Lupus nephritis (LN) is a serious and common complication of systemic lupus erythematosus (SLE) that predisposes to significant morbidity and mortality. Studies show that prompt diagnosis and treatment improves patient survival. We present a case of a 49-year-old female with an atypical presentation of LN who initially presented with new-onset hypertension, edema, arthritis, serositis and recently diagnosed leukocytoclastic vasculitis who later developed acute kidney injury, hematuria and nephrotic syndrome. Laboratory testing showed mixed cryoglobulinemia and elevated perinuclear anti-neutrophil cytoplasmic (p-ANCA) and myeloperoxidase (MPO) antibodies. SLE-related serologies were negative. Kidney biopsy showed diffuse proliferative global glomerulonephritis with a full-house nephropathy pattern on immunofluorescence suggestive of LN. Due to high clinical suspicion and renal biopsy findings, she was treated for LN with prompt renal response to immunosuppression. Cryoglobulins, p-ANCA and MPO titers normalized and the negative SLE serologies remained negative. Literature review on antinuclear antibody (ANA)-negative and seronegative LN revealed the following patient presentations: (1) renal-limited or renal and extra-renal manifestations of SLE with negative serologies and (2) renal and extra-renal manifestations of SLE with negative serologies at presentation who develop positive serologies later in follow-up. Both groups represent a unique and challenging cohort of patients who may require longer follow-up and further testing to rule out other glomerular diseases that may mimic LN on renal biopsy. The absence of SLE-related serologies should be weighed against a high pre-test probability of ANA-negative or seronegative LN. If highly suspected, the patient should be treated promptly with close monitoring.

Keywords:
Full-house nephropathy, Lupus nephritis, Negative serology, Antinuclear antibody-negative lupus, Systemic lupus erythematosus
1.
Imboden J, Hellmann DB, Stone JH: Chapter 21. Systemic Lupus Erythematosus. The McGraw-Hill Companies, Inc., 2013.
2.
Cobeñas CJ, Spizziri FD, Drut R: Membranous nephropathy and seronegative systemic lupus erythematosus. Pediatr Nephrol 2003;18:202-203.
3.
Ward MM, Pyun E, Studenski S: Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996;156:1337-1344.
4.
Alarcón GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP, PROFILE Study Group: Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002;11:95-101.
5.
Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, Roubey RA, Dooley MA: Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 2002;11:161-167.
6.
Johnson R, Feehally J, Floege J: Chapter 26: Lupus Nephritis. Elsevier Inc., 2015.
7.
Caltik A, Demircin G, Bülbül M, Erdogan O, Akyüz SG, Arda N: An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy. Rheumatol Int 2013;33:219-222.
8.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS: Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-2686.
9.
Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA: Range of antinuclear antibodies in ‘healthy' individuals. Arthritis Rheum 1997;40:1601-1611.
10.
Weening JJ, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
11.
Hochberg MC: Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
13.
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA: Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American college of pathologists. Arch Pathol Lab Med 2000;124:71-81.
14.
Malleson PN, Sailer M, Mackinnon MJ: Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997;77:299-304.
15.
von Mühlen CA Tan EM: Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-358.
16.
Wu O, Liu HH, Li WX, Zhang N, Wang Q, Li XP, Dong MX, Zhang XJ, Ye DQ: Serum soluble nucleosome and the broad family of antinucleosome antibodies are associated with organ and tissue damage in systemic lupus erythematosus in a Chinese population. Clin Exp Dermatol 2008;33:160-163.
17.
Maddison PJ, Provost TT, Reichlin M: Serological findings in patients with ‘ANA-negative' systemic lupus erythematosus. Medicine (Baltimore) 1981;60:87-94.
18.
Bagavant H, Deshmukh US, Gaskin F, Fu SM: Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage. Scand J Immunol 2004;60:52-63.
19.
Elcioglu OC, Ozkok A, Bakan A, Tuncan S, Ozluk Y, Kilicarslan I, Kanbay M, Odabas AR: A case of full-house nephropathy with anti-nuclear antibody negative lupus. Turk Nephrol Dial Transplant 2014;23:161-163.
20.
Kim HA, Chung JW, Park HJ, Joe DY, Yim HE, Park HS, Suh CH: An antinuclear antibody-negative patient with lupus nephritis. Korean J Intern Med 2009;24:76-79.
21.
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-1112.
22.
Adu D, Williams DG, Taube D, Vilches AR, Turner DR, Cameron JS, Ogg CS: Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med 1983;52:471-487.
23.
Huerta A, Bomback AS, Liakopoulos V, Palanisamy A, Stokes MB, D'Agati VD, Radhakrishnan J, Markowitz GS, Appel GB: Renal-limited ‘lupus-like' nephritis. Nephrol Dial Transplant 2012;27:2337-2342.
24.
Gianviti A, Barsotti P, Barbera V, Faraggiana T, Rizzoni G: Delayed onset of systemic lupus erythematosus in patients with ‘full-house' nephropathy. Pediatr Nephrol 1999;13:683-687.
25.
Wen YK, Chen ML: Clinicopathological study of originally non-lupus ‘full-house' nephropathy. Ren Fail 2010;32:1025-1030.
26.
Enriquez JL, Rajaraman S, Kalia A, Brouhard BH, Travis LB: Isolated antinuclear antibody-negative lupus nephropathy in young children. Child Nephrol Urol 1988-1989;9:340-346.
27.
Jones E, Magil A: Nonsystemic mesangiopathic glomerulonephritis with ‘full house' immunofluorescence. Pathological and clinical observation in five patients. Am J Clin Pathol 1982;78:29-34.
28.
Elcioglu OC, Ozkok A, Bakan A, Tuncan S, Ozluk Y, Kilicarslan I, Kanbay M, Odabas AR: A case of full-house nephropathy with anti-nuclear antibody negative lupus. Turk Nephrol Dial Transplant 2014;23:161-163.
29.
Kim HA, Chung JW, Park HJ, Joe DY, Yim HE, Park HS, Suh CH: An antinuclear antibody-negative patient with lupus nephritis. Korean J Intern Med 2009;24:76-79.
30.
Cairns SA, Acheson EJ, Corbett CL, Dosa S, Mallick NP, Lawler W, Williams G: The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis. Postgrad Med J 1979;55:723-727.
31.
Ozdemir FN, Elsurer R, Akcay A, Ozdemir BH, Sezer S, Kuscu E, Haberal M: Seronegative systemic lupus erythematosus: etiology of nephrotic syndrome and acute renal failure in early postpartum period. Lupus 2005;14:629-631.
32.
Drenkard C, Villa AR, Reyes E, Abello M, Alarcón-Segovia D: Vasculitis in systemic lupus erythematosus. Lupus 1997;6:235-242.
33.
Anders HJ, Fogo AB: Immunopathology of lupus nephritis. Semin Immunopathol 2014;36:443-459.
34.
Sharman A, Furness P, Feehally J: Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant 2004;19:1420-1426.
35.
Wen YK, Chen ML: Clinicopathological study of originally non-lupus ‘full-house' nephropathy. Ren Fail 2010;32:1025-1030.
36.
Delgado R 3rd, Frazier OH, Myers TJ, Gregoric ID, Robertson K, Shah NA, Kar B: Direct thrombolytic therapy for intraventricular thrombosis in patients with the jarvik 2000 left ventricular assist device. J Heart Lung Transplant 2005;24:231-233.
37.
Persellin RH, Takeuchi A: Antinuclear antibody-negative systemic lupus erythematosus: Loss in body fluids. J Rheumatol 1980;7:547-550.
38.
Rietveld A, Berden JH: Renal replacement therapy in lupus nephritis. Nephrol Dial Transplant 2008;23:3056-3060.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.